Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Saturday, May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NP/PAs, and other HCPs involved in the treatment and management of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the biology of DLL3 and its role as a target in SCLC due to its restricted expression profile and absence in normal adult tissues.
- Analyze the development and mechanisms of action of T-cell-engaging antibodies and CAR T-cell therapies targeting DLL3 in SCLC.
- Evaluate the latest trial data on DLL3-targeting therapies in SCLC.
- Implement strategies to monitor and mitigate common adverse effects of DLL3-targeted therapies and evidence-based management strategies.
Jacob Sands, MD
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Curadev Pharma, Daiichi-Sankyo, Fosun, Gilead, Jazz Pharmaceuticals, Lilly, Mariana Oncology, Medtronic, Merck, Novartis, Pfizer, Sanofi, Summit Therapeutics
Jennifer Carlisle, MD
Assistant Professor
Department of Hematology and Medical Oncology
Emory University
Atlanta, GA
Disclosures: Consultant: Amgen, AstraZeneca, Catalyst, Novocure; Grant/Research Support: Amgen, Chipscreen Biosciences, Daiichi Sankyo, Genentech
Hossein Borghaei, DO, MS
Professor, Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Axiom, Bayer, BeiGene, BerGenBio, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EMD-Serono, Genentech, Genmab, Gilead, Grid Therapeutics, Guardant, iTEOs, IO Biotech, Jazz, Janssen, Lilly, Merck, Mirati, Natera, Novartis, Novocure, Oncocyte, Pfizer, PharmaMar, Puma, RAPT, Regeneron, Takeda; Data and Safety Monitoring Board: Incyte, Novartis, Spring, Takeda, University of Pennsylvania: CAR T Program; Grant/Research Support: Bristol Myers Squibb, Lilly; Honorarium: Amgen, Daiichi, Janssen, Jazz, Pfizer, Regeneron; Travel: Amgen, Bristol Myers Squibb, EMD-Serono, Genentech, Jazz, Lilly, Merck, Mirati, Regeneron
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here